ChemGenex's Phantom Expanded Access Program For Omapro Cited By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
DDMAC says that there is no expanded access program for the unapproved leukemia drug Omapro (omacetaxine mepesuccinate), but even if there were one, ChemGenex would not be allowed to promote it.